Leslie V. Norwalk - Sep 1, 2023 Form 4 Insider Report for GLOBUS MEDICAL INC (GMED)

Role: Director
Signature: /s/ Kelly G. Huller, Attorney-in-Fact
Stock symbol: GMED
Transactions as of: Sep 1, 2023
Transactions value $: $0
Form type: 4
Date filed: 9/6/2023, 04:50 PM
Previous filing: Jun 20, 2023
Next filing: Jan 30, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	GMED	Class A Common Stock	Award		+2.32K			2.32K	Sep 1, 2023	Direct	F1
transaction	GMED	Class A Common Stock	Award		+25.7K	+1106.76%		28K	Sep 1, 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	GMED	Stock Option (Right to Buy Class A Common Stock)	Award	$0	+15K		$0.00	15K	Sep 1, 2023	Class A Common Stock	15K	$54.23	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, NuVasive, Inc. ("NuVasive") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into NuVasive (the "Merger"), with NuVasive continuing as a wholly owned subsidiary of the Issuer. At the effective time of the Merger (the "Effective Time"), each share of common stock of NuVasive owned by the Reporting Person was automatically converted into 0.75 shares of Class A common stock of Issuer, par value $0.001 per share ("Class A Common Stock"), and cash in lieu of fractional shares.
F2	Pursuant to the Merger Agreement, at the Effective Time of the Merger, each NuVasive restricted stock unit award was accelerated, cancelled and converted automatically into the right to receive 0.75 shares of Class A Common Stock, and cash in lieu of fractional shares, in respect of each share of NuVasive common stock underlying such award.
F3	These options were granted on September 1, 2023, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on September 1, 2024, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.